RADx® Tech and ATP Programs

word cloud with stats on RADx Tech program

The RADx® Tech/ATP programs are components of the overarching RADx Initiative at NIH to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The RADx Tech/ATP innovation funnel was designed to compress the customary technology development timeline from years down to just months.  This was accomplished by employing, in parallel, expert teams to address technical, regulatory, clinical, and commercialization requirements. Launched on April 29, 2020, the RADx programs were able to validate, de-risk, scale up, manufacture, and deploy novel tests through a seamless pipeline by fall 2020. 

These programs have increased testing capacity in the U.S. by billions. As the COVID-19 pandemic evolves, NIBIB continues to support projects to fill unmet needs in diagnostic testing. 

The MakeMyTestCount.org website is an easy way to anonymously report test results for any brand of at-home COVID-19 test. This helps public health departments to assess needs and provide resources. Report your test results here

Learn about a fast, cost-effective method to detect the circulation of SARS-CoV-2 variants using a genotyping approach. 

When to Test tool now has an individual calculator to help guide individuals and families on COVID-19 testing. The Testing Impact Calculator also includes tools to help organizations plan for and develop testing strategies, and playbooks for pooled testing and K-12 schools. This site includes other resources on testing strategies and obtaining supplies. Try the calculator.

generic bar chart titled tests produced

Program Dashboard

Summary data on proposals submitted to the RADx Tech and ATP Programs.

  • 7 billion tests and test products produced 
  • 51 FDA authorizations
  • 1st over-the-counter test for use at home
  • >100 companies supported
photo of women using nasal swab

Authorized Tests

List of RADx Tech/ATP supported lab, point-of-care, and over-the-counter/at-home tests and test products that have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).  

timeline starting at 2020 with milestones

RADx® Tech Timeline

See the milestones and success that have unfolded since the beginning of the RADx Tech program.

Available Now: Best Practice Recommendations document for designing and developing COVID-19 tests that are more accessible. This is part of the RADx Tech effort to work with collaborators to develop at-home diagnostic tests for COVID-19 that can be used independently by people with disabilities. The initial focus is with people who are blind or have low vision, people with fine motor difficulties, and home tests for older adults. 

Learn more about this accelerated pathway designed to help bring to market over the counter diagnostic tests for COVID-19 that are not yet authorized by the FDA.

Learn about this effort to securely send results from a self-administered test to public health systems. The process is designed to work with different tests and includes an option for anonymous reporting. 

The Say Yes COVID Test project is a cooperative effort from state and local health departments, NIH, and CDC.  This program offers access to free, rapid, at-home COVID-19 testing in select communities throughout the U.S. Learn more.  

Information about studies to evaluate diagnostic tests being developed for COVID-19.

This webinar series hosted by POCTRN provides information on RADx® Tech/ATP program activities.  Register for upcoming events or watch previous webinars.

RADx Testing

Tests in Development

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

RADx Tech organization chart


The RADx Tech and ATP programs leverage the Point of Care Technology Research Network and joined with numerous other federal agencies, offices, NIH institutes, and contractors.

3D rendering of SARS-CoV-2

RADX Tech Solicitations

There are currently no funding opportunities.  For information on the most recent RADx Tech III opportunity see Frequently Asked Questions (FAQs).


Program Contacts

Program Contacts

Current grantees contact Program Director on your existing award.

RADx® Tech programmatic or technical inquiries: info.radx@poctrn.org

All other RADx® Tech Applicants: RADxNIBIB@mail.nih.gov

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov

All others: COVID19Grants@nih.gov

Related News

January 5, 2023
Text that reads Home Test to Treat Program, Powered By eMed. Above the “o” in “Home,” there is a simple illustration of a roof and chimney.
NIH has launched the Home Test to Treat program, an entirely virtual community health intervention that will provide free COVID-19 health services—at-home rapid tests, telehealth sessions and at-home treatments—in selected communities.
November 22, 2022
Light blue map of the United States overlayed with Make My Test Count.org
Reporting a positive or negative test result just became easier through a new website from the National Institutes of Health. MakeMyTestCount.org, developed through NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program, allows users to anonymously report the results of any brand of at-home COVID-19 test.
November 18, 2022
shades of blue concept image of outline of head, brain and network connections
The National Institutes of Health has awarded research funding for seven pilot projects developing early stage, yet groundbreaking neuro-technologies. The innovative projects would enable new medical devices to diagnose and treat both acute and chronic disorders, from neuropathic pain to mental illness.
October 17, 2022
stylized snake design
NIBIB Director Bruce J. Tromberg, Ph.D., has been elected to membership in the National Academy of Medicine.
September 15, 2022
Illustration of SARS-CoV-2 viral particles in different colors on a blue background
A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.